^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HYML-122
i
Other names: HYML-122, HYLM-122
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Tarapeutics Science, Youyuan Pharma
Drug class:
FLT3 inhibitor
Related drugs:
7ms
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P2, N=15, Recruiting, Tarapeutics Science Inc. | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Mar 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3 mutation
|
HYML-122
7ms
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P2, N=18, Recruiting, Tarapeutics Science Inc. | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3 mutation
|
cytarabine • HYML-122
over1year
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P2, N=15, Recruiting, Tarapeutics Science Inc. | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
Trial completion date • Trial primary completion date
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3 mutation
|
HYML-122
over1year
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P2, N=18, Recruiting, Tarapeutics Science Inc. | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
Trial completion date • Trial primary completion date
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3 mutation
|
cytarabine • HYML-122
Share via
